<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
SPRY
ARS Pharmaceuticals
$
()


  • ARS Pharmaceuticals submits response to FDA's CRL for neffy nasal spray

    4/3/2024 - 09:19am
  • ARS Pharmaceuticals reports FY23 EPS (57c), consensus (14c)

    3/21/2024 - 16:16pm
  • ARS Pharmaceuticals to hold virtual investor day

    3/7/2024 - 12:25pm
  • ARS Pharmaceuticals to hold virtual investor day

    3/7/2024 - 04:55am
  • ARS Pharmaceuticals to hold virtual investor day

    3/7/2024 - 00:05am
  • Lyft upgraded, Philip Morris downgraded: Wall Street's top analyst calls

    3/5/2024 - 09:45am
  • ARS Pharmaceuticals just upgraded at Leerink, here's why

    3/5/2024 - 06:09am
  • ARS Pharmaceuticals reports neffy meets primary endpoints in Phase 2 study

    2/26/2024 - 09:04am
  • ARS Pharmaceuticals just upgraded at William Blair, here's why

    2/20/2024 - 11:32am
  • ARS Pharmaceuticals announces results from repeat dosing study of neffy

    2/20/2024 - 09:15am
  • ARS Pharmaceuticals to present efficacy data for neffy at 2024 AAAAI meeting

    2/5/2024 - 09:12am
  • ARS Pharmaceuticals price target raised to $13 from $5 at Wedbush

    11/13/2023 - 07:38am
  • ARS Pharmaceuticals reports Q3 EPS (16c), consensus (18c)

    11/9/2023 - 16:10pm
  • ARS Pharmaceuticals presents clinical data on neffy for allergic reactions

    11/9/2023 - 11:07am
  • ARS Pharmaceuticals announces scheduling of Type A meeting with FDA for neffy

    10/6/2023 - 09:08am
dynamic_feed Breaking News